

DR PETER MEINTJES COMMENCES AS PACIFIC EDGE CHIEF EXECUTIVE OFFICER

Cancer diagnostics company Pacific Edge (NZX: PEB, ASX: PEB) announces Dr Peter Meintjes commenced as Chief Executive Officer of the company on 17 January.

As announced in October 2021, Dr Meintjes replaces Executive Director and Chief Executive David Darling, who announced his retirement in April 2021.

Pacific Edge Chairman Chris Gallaher said: "We are delighted to welcome Peter to Pacific Edge. We are confident his deep experience in molecular diagnostics, particularly in the US market, will be of tremendous value as the company moves into its next phase of growth."

Dr Meintjes, who has relocated from Boston to New Zealand with his family, will be based in the company's Dunedin Head Office.

Peter succeeds David Darling who has now stepped down as CEO and as a Director on the Pacific Edge Board. He remains as a consultant to the company.

For more information contact: Dr Peter Meintjes, Pacific Edge. P: +64 22 0321 263 E: peter.meintjes@pelnz.com

For media assistance, please contact: Richard Inder, The Project. P: +64 21 645 643 E: richard@theproject.co.nz

OVERVIEW www.pacifiedge.co.nz www.pacifiedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late-stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.